Personalized asthma management in pediatric patients based on treatment response

References

• Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: national health interview survey. Vital Health Stat. 2010;250:1–80.
   Google Scholar
• Moorman JE, Akinbami LJ, Bailey CM, et al. National surveillance of asthma: united States, 2001-2010. Vital Health Stat. 2012;35(3):1–58.
   Google Scholar
• Newacheck PW, Halfon N. Prevalence, impact, and trends in childhood disability due to asthma. Arch Pediatr Adolesc Med. 2000;154(3):287–293.
   PubMedGoogle Scholar
• Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–976.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Wenzel S, Brown R, et al., Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012:129(3 Suppl): S9–S23.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention, 2020. Available from: www.ginasthma.org.
   Google Scholar
• Pavord ID. Blood eosinophil-directed management of airway disease: the past, present and future. Am J Respir Crit Care Med. 2020;202(5):637–639.
   PubMed Web of Science ®Google Scholar
• Shrimanker R, Keene O, Hynes G, et al. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a. Am J Respir Crit Care Med. 2019;200(10):1308–1312.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al., T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009:180(5): 388–395.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323(15):1033–1039.
   PubMed Web of Science ®Google Scholar
• Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113(1):101–108.
   PubMed Web of Science ®Google Scholar
• Lowell FC. Clinical aspects of eosinophilia in atopic disease. JAMA. 1967;202(9):875–878.
   PubMed Web of Science ®Google Scholar
• Horn BR, Robin ED, Theodore J, et al. Total eosinophil counts in the management of bronchial asthma. N Engl J Med. 1975;292(22):1152–1155.
   PubMed Web of Science ®Google Scholar
• Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005;352(15):1519–1528.
   PubMed Web of Science ®Google Scholar
• Kansal P, Nandan D, Agarwal S, et al. Correlation of induced sputum eosinophil levels with clinical parameters in mild and moderate persistent asthma in children aged 7-18 years. J Asthma. 2018;55(4):385–390.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Jackson DJ, Mauger DT, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608–1618.e12.
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715–1721.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751.
   PubMed Web of Science ®Google Scholar
• Gupta A, Ikeda M, Geng B, et al., Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019:144(5): 1336–1342.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al., Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018:378(26): 2486–2496.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al., Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018 [cited 2020 Jul 25]:378(26): 2475–2485.
   PubMed Web of Science ®Google Scholar
• Spahn JD, Malka J, Szefler SJ. Current application of exhaled nitric oxide in clinical practice. J Allergy Clin Immunol. 2016;138(5):1296–1298.
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117(1):45–52.
   PubMed Web of Science ®Google Scholar
• Pijnenburg MW, Hofhuis W, Hop WC, et al. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax. 2005;60(3):215–218.
   PubMed Web of Science ®Google Scholar
• Chang DV, Teper A, Balinotti J, et al. Exhaled nitric oxide predicts loss of asthma control in children after inhaled corticosteroids withdrawal. Pediatr Pulmonol. 2019;54(5):537–543.
   PubMed Web of Science ®Google Scholar
• Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy. 2004;59(5):469–478.
   PubMed Web of Science ®Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615.
   PubMed Web of Science ®Google Scholar
• Fielding S, Pijnenburg M, de Jongste JC, et al. Change in FEV. Chest. 2019;155(2):331–341.
   PubMedGoogle Scholar
• Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012;67(3):199–208.
   PubMed Web of Science ®Google Scholar
• Dressel H, de la Motte D, Reichert J, et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med. 2008 2; 102(7): 962–969.
   PubMed Web of Science ®Google Scholar
• Taylor DR, Mandhane P, Greene JM, et al. Factors affecting exhaled nitric oxide measurements: the effect of sex. Respir Res. 2007;8:82.
   PubMed Web of Science ®Google Scholar
• Komakula S, Khatri S, Mermis J, et al. Body mass index is associated with reduced exhaled nitric oxide and higher exhaled 8-isoprostanes in asthmatics. Respir Res. 2007;8:32.
   PubMed Web of Science ®Google Scholar
• Buchvald F, Baraldi E, Carraro S, et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. J Allergy Clin Immunol. 2005;115(6):1130–1136.
   PubMed Web of Science ®Google Scholar
• Gratziou C, Lignos M, Dassiou M, et al. Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis. Eur Respir J. 1999;14(4):897–901.
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: evidence From PROSPERO, A Prospective Real-World Study. J Allergy Clin Immunol Pract. 2019;7(1):156–164.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the national institutes of health/national heart, lung, and blood institute severe asthma research program. J Allergy Clin Immunol. 2011;127(2):382–389.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.
   PubMed Web of Science ®Google Scholar
• Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2003;111(2):278–284.
   PubMed Web of Science ®Google Scholar
• Kulus M, Hébert J, Garcia E, et al. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin. 2010;26(6):1285–1293.
   PubMed Web of Science ®Google Scholar
• Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–1444.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al., Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011:364(11): 1005–1015.
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al., Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015:136(6): 1476–1485.
   PubMed Web of Science ®Google Scholar
• Esquivel A, Busse WW, Calatroni A, et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 2017;196(8):985–992.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Casale TB, Haselkorn T, et al. Treatment benefit with omalizumab in children by indicators of asthma severity. J Allergy Clin Immunol Pract. 2020 Apr;8(8):2673–2680.e3.
   Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60(3):302–308.
   PubMed Web of Science ®Google Scholar
• Johansson MW, Evans MD, Crisafi GM, et al. Serum periostin is associated with type 2 immunity in severe asthma. J Allergy Clin Immunol. 2016;137(6):1904–1907.
   PubMed Web of Science ®Google Scholar
• Conway SJ, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014;71(7):1279–1288.
   PubMed Web of Science ®Google Scholar
• Licari A, Brambilla I, Sacchi L, et al. Periostin, type 2 biomarker, is not associated with asthma control grade in asthmatic allergic children. Respir Med. 2019;151:118–120.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–796.
   PubMed Web of Science ®Google Scholar
• Ying S, O’Connor B, Ratoff J, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol. 2005;174(12):8183–8190.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017;377(10):936–946.
   PubMed Web of Science ®Google Scholar
• Schleich FN, Zanella D, Stefanuto PH, et al. Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. Am J Respir Crit Care Med. 2019;200(4):444–453.
   PubMed Web of Science ®Google Scholar
• Neerincx AH, Vijverberg SJH, Bos LDJ, et al. Breathomics from exhaled volatile organic compounds in pediatric asthma. Pediatr Pulmonol. 2017;52(12):1616–1627.
   PubMed Web of Science ®Google Scholar
• Caldeira M, Barros AS, Bilelo MJ, et al. Profiling allergic asthma volatile metabolic patterns using a headspace-solid phase microextraction/gas chromatography based methodology. J Chromatogr A. 2011;1218(24):3771–3780.
   PubMed Web of Science ®Google Scholar
• van Vliet D, Smolinska A, Jöbsis Q, et al. Can exhaled volatile organic compounds predict asthma exacerbations in children? J Breath Res. 2017;11(1):016016.
   PubMed Web of Science ®Google Scholar
• Smolinska A, Hauschild AC, Fijten RR, et al. Current breathomics–a review on data pre-processing techniques and machine learning in metabolomics breath analysis. J Breath Res. 2014;8(2):027105.
   PubMed Web of Science ®Google Scholar
• Gern JE. The urban environment and childhood asthma study. J Allergy Clin Immunol. 2010;125(3):545–549.
   PubMed Web of Science ®Google Scholar
• Yang IV, Pedersen BS, Liu A, et al. DNA methylation and childhood asthma in the inner city. J Allergy Clin Immunol. 2015;136(1):69–80.
   PubMed Web of Science ®Google Scholar
• Altman MC, Gill MA, Whalen E, et al. Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children. Nat Immunol. 2019;20(5):637–651.
   PubMed Web of Science ®Google Scholar
• McCauley K, Durack J, Valladares R, et al. Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma. J Allergy Clin Immunol. 2019;144(5):1187–1197.
   PubMed Web of Science ®Google Scholar
• Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. 1997;336(19):1356–1363.
   PubMed Web of Science ®Google Scholar